HOME >> BIOLOGY >> NEWS
NIH funds innovative alzheimer's research initiated at UCSB

A completely new approach to the study of Alzheimers disease, initiated by a professor at the University of California, Santa Barbara, may solve a critical piece in the puzzle of the disease. This tragic neurological illness progressively erases memory in its millions of victims. The key to the new approach is understanding the way certain proteins in the brain fold, or rather misfold.

Michael Bowers, a professor in the Department of Chemistry and Biochemistry, developed this project, which is being funded by the National Institutes of Health. Bowerss laboratory will receive $1.3 million of the total $9 million project grant, plus biological samples worth an additional $500,000. The grant covers a five-year period. Four institutions are involved.

Bowers is using specialized chemical research methods and applying them to biology. His research will depend upon the study of rare peptides, or strings of amino acids, that are difficult to produce. These will be provided by co-investigator David Teplow, a professor at UCLAs David Geffen School of Medicine, who has been involved in Alzheimers research for over 10 years. Joan-Emma Shea, also a professor in UCSBs Department of Chemistry and Biochemistry, heads the theoretical modeling aspect of the project.

Until about five or six years ago, everyone assumed that the large amyloid plaques, or neurofibrillary tangles, that were found in the brains of Alzheimers victims were the cause of the disease, said Bowers. However, recent scientific discoveries indicate that these large, insoluble aggregates might merely be markers of the disease they do not cause the disease. Rather, smaller soluble oligomers, or peptide complexes, are now felt to be the causative agents, and I find that very interesting.

He explained that now the hunt is on for the small stuff. Because of their expertise in certain chemical methodologies, Bowers and his research group are able to track down the molecular l
'"/>

Contact: Gail Gallessich
gail.g@ia.ucsb.edu
805-893-7220
University of California - Santa Barbara
14-Feb-2007


Page: 1 2 3 4

Related biology news :

1. The Cancer Genome Atlas awards funds for technology development
2. NSF funds new Rutgers plant biomaterials initiative
3. NSF funds biofertilizer research at Rutgers-Camden
4. ResearchChannel awards matching funds for video production
5. Research grant funds studies of climate change and reef ecosystems
6. NHGRI funds large-scale sequencing centers
7. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device
8. Worcester Polytechnic Institute receives $2 million in federal funds for biomedical research centers
9. Columbia University Medical Center receives major new NIH Clinical Science investment funds
10. NIH funds Berkeley Lab research on defense against radiological attack
11. NIH funds 14 High-End Instrumentation grants

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NIH funds innovative alzheimer research initiated UCSB

(Date:2/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... CEO Conference on January 29 th at 10:30 ... CEO of NXT-ID will present and host a live ... wallet and its full suite of biometric technologies. Investors ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
(Date:3/5/2015)... NORWALK, Conn. , March 5, 2015 /PRNewswire/ ... Network , a leading online community to ... understanding of the newest information available regarding the ... coverage of kidney cancer. March is ... there are very few effective adjuvant treatment options ...
(Date:3/5/2015)... March 5, 2015  In response to the incorrect ... Miami, FL on February 12, 2015. Impeto ... strong financial health and their SUDOSCAN® devices have been ... indicated. Furthermore, Impeto prefers to have the courts decide this ... more than 40 articles written by Key Opinion Leaders, ...
(Date:3/5/2015)... 05, 2015 The next implants made ... the CE mark (European) approval. The CE mark is ... Association (EFTA) and the European Union. Following the Class ... granted to implants supplied by the Turkey-based company Osimplant ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage line ...
(Date:3/4/2015)... INCLINE VILLAGE, Nev. , March 4, 2015 PDL ... that the adjusted conversion rate for the: , ... Notes), is 174.8506 shares of common stock per $1,000 principal ... The conversion rate for the note is adjusted ... be paid on March 12, 2015, to all stockholders who own ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
Cached News: